Related Experiment Video
Updated: Jun 15, 2026

Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
Solution structure of LC5, the CCR5- derived peptide for HIV-1 inhibition
Kazuhide Miyamoto1, Kayo Togiya, Ryo Kitahara
1Department of Pharmaceutical Health Care, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Hyogo, Japan. miyamoto@himeji-du.ac.jp
Abstract:
The synthetic peptide fragment (LC5: LRCRNEKKRHRAVRLIFTI) inhibits human immunodeficiency virus type 1 (HIV-1) infection of MT-4 cells. In this study, the solution structure of LC5 in SDS micelles was elucidated by using the standard (1)H two-dimensional NMR spectroscopic method along with circular dichroism and fluorescence quenching. The peptide adopts a helical structure in the C-terminal region (residues 13-16), whereas the N-terminal part remains unstructured. The importance of Phe17 in maintaining the structure of LC5 was demonstrated by replacing Phe17 with Ala, which resulted in the dramatic conformational change of LC5. The solution structure of LC5 elucidated in the present work provides a basis for further study of the mechanism of the inhibition of HIV-1 infection.
More Related Videos
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors

